Research programme: serotonin 6 receptor antagonists - AbbVieAlternative Names: A-964324
Latest Information Update: 05 Feb 2013
At a glance
- Originator Abbott Laboratories
- Mechanism of Action Serotonin 6 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Alzheimer's disease; Schizophrenia